[1] Sung H, Ferlay J, Siegel RL, et al. Globalcancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2021,71(3):209-249.
[2] 郑树森. 肝细胞癌患者肝移植后应用mTOR抑制剂预防肿瘤复发的研究进展. 中华器官移植杂志,2011,32(8):453-456.
[3] Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol, 2021, 15(1):91-102.
[4] Chagas AL, Felga GEG, Diniz MA, et al. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol, 2019, 31(9):1148-1156.
[5] Valdivieso A, Bustamante J, Gastaca M, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc, 2010, 42(2):660-662.
[6] Yang Z, Wang S, Tian XY, et al. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int, 2020, 19(4):365-370.
[7] Jeong YH, Hwang S, Lee GD, et al. Surgical outcome of pulmonary metastasectomy for hepatocellular carcinoma recurrence in liver transplant patients. Ann Transplant, 2021, 26:e930383.
[8] Fernandez-Sevilla E, Allard MA, Selten J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection? Liver Transpl, 2017, 23(4):440-447.
[9] Liu B, Huang G, Xie X, et al. Feasibility and outcomes of percutaneous radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma after liver transplantation: a single-center experience. Int J Hyperthermia, 2020, 37(1):1202-1209.
[10] Yang W, Wu H, Zhang ZY, et al. Long-term outcome of percutaneous radiofrequency ablation in recurrent hepatocellular carcinoma after liver transplantation. Int J Hyperthermia, 2018, 34(1):68-76.
[11] Zhai H, Liang P, Yu XL, et al. Microwave ablation in treating intrahepatic recurrence of hepatocellular carcinoma after liver transplantation: An analysis of 11 cases. Int J Hyperthermia, 2015, 31(8):863-868.
[12] Akhan O, Sarikaya Y, Köksal A, et al. Irreversible electroporation of recurrent hepatocellular carcinoma after liver transplantation: Report of two cases. Cardiovasc Intervent Radiol, 2021, 44(5):807-811.
[13] 孙静,张爱民,李文刚,等. 28例大肝细胞癌立体定向放疗疗效观察. 中华放射肿瘤学杂志,2019,28 (10): 749-752.
[14] Eriguchi T, Takeda A, Tateishi Y, et al. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies. Hepatol Res, 2021, 51(7):813-822.
[15] Au KP, Chiang CL, Chan ACY, et al. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation. World J Clin Cases, 2020, 8(13):2758-2768.
[16] Cheng YC, Chen TW, Fan HL, et al. Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation. Ann Transplant, 2014, 19:309-316.
[17] Abdelrahim M, Victor D, Esmail A, et al. Transarterial chemoembolization (TACE) plus sorafenib compared to TACE alone in transplant recipients with hepatocellular carcinoma: An institution experience. Cancers (Basel), 2022, 14(3):650.
[18] de'Angelis N, Landi F, Carra MC, et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol, 2015, 21(39):11185-11198.
[19] Jeng LB, Lee SG, Soin AS, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant, 2018, 18(6):1435-1446.
[20] Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial. Transplantation, 2016, 100(1):116-125.
[21] Lee SG, Jeng LB, Saliba F, et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. Transplantation, 2021, 105(7):1564-1575.
[22] Li BCW, Chiu J, Shing K, et al. The outcomes of systemic treatment in recurrent hepatocellular carcinomas following liver transplants. Adv Ther, 2021, 38(7):3900-3910.
[23] López Ortega S, González Grande R, Santaella Leiva I, et al. Efficacy and safety of sorafenib after liver transplantation: experience in our center. Transplant Proc, 2020, 52(2):540-542.
[24] 刘奇,郝吉庆.免疫联合治疗肝细胞癌研究进展.实用肝脏病杂志, 2021,24(1):7-9.
[25] Friend BD, Venick RS, McDiarmid SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer, 2017, 64(12):10.
[26] DeLeon TT, Salomao MA, Aqel BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol, 2018, 9(6):1054-1062.
[27] Shi GM, Wang J, Huang XW, et al. Graft programmed death ligand 1 expression as a marker for transplant rejection following anti-programmed death 1 immunotherapy for recurrent liver tumors. Liver Transpl, 2021, 27(3):444-449.
[28] De Toni EN, Gerbes AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient. Gastroenterology, 2017, 152(6):1631-1633.
[29] Amjad W, Kotiah S, Gupta A, et al. Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab. J Clin Exp Hepatol, 2020, 10(2):185-187. |
